XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
6.50% Convertible Senior Notes Due 2024
August 2019 Bonds
Preferred stock
Common stock
Common stock
6.50% Convertible Senior Notes Due 2024
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
6.50% Convertible Senior Notes Due 2024
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2018       23 97,225,810                
Beginning balance at Dec. 31, 2018 $ 87,032,407     $ 0 $ 97,226     $ 707,794,215     $ (620,426,436) $ (528,867) $ 96,269
Issuance of common stock for cash (in shares)         183,200                
Issuance of common stock for cash 907,330       $ 183     907,147          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         525,000                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (719,397)       $ 525     (719,922)          
Equity component of issuance of convertible notes 15,752,698             15,752,698          
Stock-based compensation 3,432,796             3,432,796          
Acquisition of non-controlling interest in Geneos 3,030,107                       3,030,107
Net loss attributable to common stockholders (29,288,867)                   (29,219,262)   (69,605)
Unrealized gain (loss) on short-term investments, net of tax 819,177                     819,177  
Ending balance (in shares) at Mar. 31, 2019       23 97,934,010                
Ending balance at Mar. 31, 2019 80,966,251     $ 0 $ 97,934     727,166,934     (649,645,698) 290,310 3,056,771
Beginning balance (in shares) at Dec. 31, 2018       23 97,225,810                
Beginning balance at Dec. 31, 2018 87,032,407     $ 0 $ 97,226     707,794,215     (620,426,436) (528,867) 96,269
Net loss attributable to common stockholders (82,404,395)                        
Unrealized gain (loss) on short-term investments, net of tax 1,229,265                        
Foreign currency translation 0                        
Ending balance (in shares) at Sep. 30, 2019       23 99,046,158                
Ending balance at Sep. 30, 2019 36,118,732     $ 0 $ 99,046     735,017,743     (702,123,617) 700,398 2,425,162
Beginning balance (in shares) at Mar. 31, 2019       23 97,934,010                
Beginning balance at Mar. 31, 2019 80,966,251     $ 0 $ 97,934     727,166,934     (649,645,698) 290,310 3,056,771
Issuance of common stock for cash (in shares)         476,600                
Issuance of common stock for cash 1,388,986       $ 476     1,388,510          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         173,761                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (81,259)       $ 174     (81,433)          
Stock-based compensation 3,355,195             3,345,378         9,817
Cost of acquisition of non-controlling interest in Geneos (13,569)                       (13,569)
Net loss attributable to common stockholders (29,579,076)                   (29,387,226)   (191,850)
Unrealized gain (loss) on short-term investments, net of tax 441,545                     441,545  
Ending balance (in shares) at Jun. 30, 2019       23 98,584,371                
Ending balance at Jun. 30, 2019 56,478,073     $ 0 $ 98,584     731,819,389     (679,032,924) 731,855 2,861,169
Issuance of common stock for cash (in shares)         382,800                
Issuance of common stock for cash 1,128,749       $ 383     1,128,366          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         78,987                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 0       $ 79     (79)          
Stock-based compensation 2,079,819             2,070,067         9,752
Net loss attributable to common stockholders (23,536,452)                   (23,090,693)   (445,759)
Unrealized gain (loss) on short-term investments, net of tax (31,457)                     (31,457)  
Foreign currency translation 0                        
Ending balance (in shares) at Sep. 30, 2019       23 99,046,158                
Ending balance at Sep. 30, 2019 36,118,732     $ 0 $ 99,046     735,017,743     (702,123,617) 700,398 2,425,162
Beginning balance (in shares) at Dec. 31, 2019       23 101,361,034                
Beginning balance at Dec. 31, 2019 5,404,858     $ 0 $ 101,361     742,646,785     (739,785,655) 472,608 1,969,759
Issuance of common stock for cash (in shares)         43,148,952                
Issuance of common stock for cash 208,241,933       $ 43,149     208,198,784          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         1,405,114                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,100,703       $ 1,405     3,099,298          
Stock-based compensation 4,001,553             4,017,761         (16,208)
Acquisition of non-controlling interest in Geneos 2,169,998                       2,169,998
Net loss attributable to common stockholders (33,135,404)                   (32,541,054)   (594,350)
Unrealized gain (loss) on short-term investments, net of tax (1,929,538)                     (1,929,538)  
Ending balance (in shares) at Mar. 31, 2020       23 145,915,100                
Ending balance at Mar. 31, 2020 187,854,103     $ 0 $ 145,915     957,962,628     (772,326,709) (1,456,930) 3,529,199
Beginning balance (in shares) at Dec. 31, 2019       23 101,361,034                
Beginning balance at Dec. 31, 2019 5,404,858     $ 0 $ 101,361     742,646,785     (739,785,655) 472,608 1,969,759
Net loss attributable to common stockholders (143,136,534)                        
Unrealized gain (loss) on short-term investments, net of tax (726,626)                        
Foreign currency translation 6,184                        
Ending balance (in shares) at Sep. 30, 2020       9 167,528,435                
Ending balance at Sep. 30, 2020 324,000,115     $ 0 $ 167,527     1,205,842,585     (881,858,432) (247,834) 96,269
Beginning balance (in shares) at Mar. 31, 2020       23 145,915,100                
Beginning balance at Mar. 31, 2020 187,854,103     $ 0 $ 145,915     957,962,628     (772,326,709) (1,456,930) 3,529,199
Issuance of common stock for cash (in shares)         12,041,178                
Issuance of common stock for cash 121,718,922       $ 12,041     121,706,881          
Conversion of preferred stock to common stock (in shares)       (14) (5,147)                
Conversion of preferred stock to common stock 0       $ 5     (5)          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         794,986                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 4,422,244       $ 795     4,421,449          
Stock-based compensation 3,662,435             3,654,289         8,146
Acquisition of non-controlling interest in Geneos 209,971                       209,971
Deconsolidation of Geneos (3,181,640)                       (3,181,640)
Net loss attributable to common stockholders (129,172,466)                   (128,703,059)   (469,407)
Unrealized gain (loss) on short-term investments, net of tax 846,900                     846,900  
Ending balance (in shares) at Jun. 30, 2020       9 158,756,411                
Ending balance at Jun. 30, 2020 186,360,469     $ 0 $ 158,756     1,087,745,242     (901,029,768) (610,030) 96,269
Conversion of preferred stock to common stock (in shares)           (3,546,074) (4,962,364)            
Conversion of preferred stock to common stock   $ 12,971,360 $ 102,671,310     $ 3,546 $ 4,961   $ 12,967,814 $ 102,666,349      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         263,586                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,695,051)       $ 264     (1,695,315)          
Stock-based compensation 4,158,495             4,158,495          
Net loss attributable to common stockholders 19,171,336                   19,171,336    
Unrealized gain (loss) on short-term investments, net of tax 356,012                     356,012  
Foreign currency translation 6,184                     6,184  
Ending balance (in shares) at Sep. 30, 2020       9 167,528,435                
Ending balance at Sep. 30, 2020 $ 324,000,115     $ 0 $ 167,527     $ 1,205,842,585     $ (881,858,432) $ (247,834) $ 96,269